{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:00:56Z","timestamp":1790114456110,"version":"4.0.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Subanesthetic ketamine may reduce perioperative consumption of opioids. We studied whether intravenous S-ketamine alters the pharmacokinetics of oral morphine in healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      In this paired, randomized, double-blind, crossover trial, 12 participants under a 2-hour intravenous S-ketamine (0.57 mg\/kg\/h) or placebo infusion received oral morphine (0.2 mg\/kg) at 30 minutes. Plasma concentrations of ketamine, morphine, and their major metabolites were quantified for 24 hours. The primary end point was area under the curve (AUC)\n                      <jats:sub>0\u201324<\/jats:sub>\n                      of morphine. Other pharmacokinetic variables for morphine and its metabolites were studied as secondary end points. The data were analyzed as between-phase comparisons for each participant using Wilcoxon matched-pairs signed-rank tests (\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ) or paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -tests on log-transformed variables (other variables).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      While the AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      was similar between the 2 phases, S-ketamine reduced the AUC\n                      <jats:sub>0\u20131.5<\/jats:sub>\n                      of oral morphine by 69% (ratio to control, 0.31; 90% confidence interval [CI], 0.15\u20130.65;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0171) and increased its\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      from 0.5 (range, 0.50\u20131.5) to 1.0 hour (range, 0.50\u20134.0;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .010). The AUC\n                      <jats:sub>0\u20131.5<\/jats:sub>\n                      of morphine-6-glucuronide (M6G) was reduced by 84% (0.16; 90% CI, 0.07\u20130.37;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0025) and maximum plasma concentration (\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ) by 43% (0.57; 90% CI, 0.40\u20130.81;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0155), while its\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      was increased from 1.5 (range, 1.0\u20132.0) to 4.0 (range, 1.0\u20138.0;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0094) hours by S-ketamine. Similarly, the AUC\n                      <jats:sub>0\u20131.5<\/jats:sub>\n                      of morphine-3-glucuronide (M3G) was reduced by 85% (0.15; 90% CI, 0.05\u20130.43;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0083), and\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      increased from 1.0 (range, 0.5\u20131.5) to 4.0 hours (range, 1.0\u20138.0;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0063). In addition, the M6G-to-morphine and M3G-to-morphine metabolic AUC ratios were decreased by 47% (0.53; 90% CI, 0.39\u20130.71;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0033) and 52% (0.48; 90% CI, 0.27\u20130.85;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0043) during 0 to 1.5 hours and by 15% (0.85; 90% CI, 0.78\u20130.92;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0057) and 10% (0.90; 90% CI, 0.83\u20130.98;\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      .0468) during 0 to 24 hours, respectively. One participant was excluded from the analyses due to vomiting in the S-ketamine phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Intravenous S-ketamine inhibited the metabolism of oral morphine and delayed its absorption, resulting in a net reduction in the exposure to morphine during the first 1.5 hours. Intravenous S-ketamine may delay the absorption and impair the efficacy of orally administered analgesics and other drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000006640","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T13:02:15Z","timestamp":1695301335000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Influence of Intravenous S-Ketamine on the Pharmacokinetics of Oral Morphine in Healthy Volunteers"],"prefix":"10.1213","volume":"138","author":[{"given":"Terhi J.","family":"Lohela","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Poikola","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Backmansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Lapatto-Reiniluoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"HUS Pharmacy, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus T.","family":"Olkkola","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas O.","family":"Lilius","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Finnish Poison Information Center, Department of Emergency Medicine and Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.bja.2019.02.018","article-title":"Are opioids indispensable for general anaesthesia?","volume":"122","author":"Egan","year":"2019","journal-title":"Br J Anaesth"},{"key":"R2-20250502","first-page":"Cd012592","article-title":"Opioids for cancer pain\u2014an overview of Cochrane reviews.","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/ALN.0000000000003572","article-title":"Perioperative opioid administration: a critical review of opioid-free versus opioid-sparing approaches.","volume":"134","author":"Shanthanna","year":"2021","journal-title":"Anesthesiology"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ALN.0000000000003705","article-title":"Opioid-free anesthesia: time to regain our balance.","volume":"134","author":"Kharasch","year":"2021","journal-title":"Anesthesiology"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(19)30430-1","article-title":"Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia.","volume":"393","author":"Colvin","year":"2019","journal-title":"Lancet"},{"key":"R6-20250502","first-page":"Cd012033","article-title":"Perioperative intravenous ketamine for acute postoperative pain in adults.","volume":"12","author":"Brinck","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy.","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250502","first-page":"Cd003351","article-title":"Ketamine as an adjuvant to opioids for cancer pain.","volume":"6","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/EJA.0000000000000877","article-title":"Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: a randomised controlled trial.","volume":"36","author":"Boenigk","year":"2019","journal-title":"Eur J Anaesthesiol"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0304-3959(99)00096-2","article-title":"Low-dose subcutaneous ketamine infusion and morphine tolerance.","volume":"83","author":"Bell","year":"1999","journal-title":"Pain"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0885-3924(98)00144-4","article-title":"Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.","volume":"17","author":"Fine","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.1824728","article-title":"Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.","volume":"251","author":"Trujillo","year":"1991","journal-title":"Science"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3959(98)00269-3","article-title":"Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine.","volume":"81","author":"Shimoyama","year":"1999","journal-title":"Pain"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0014-2999(97)01099-6","article-title":"Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists.","volume":"332","author":"Gonz\u00e1lez","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00000539-200001000-00030","article-title":"Spinal coadministration of ketamine reduces the development of tolerance to visceral as well as somatic antinociception during spinal morphine infusion.","volume":"90","author":"Miyamoto","year":"2000","journal-title":"Anesth Analg"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2012.42.1081","article-title":"Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain.","volume":"30","author":"Hardy","year":"2012","journal-title":"J Clin Oncol"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/jpm.2011.0353","article-title":"Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care.","volume":"15","author":"Salas","year":"2012","journal-title":"J Palliat Med"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/dmd.109.030957","article-title":"Inhibition of morphine metabolism by ketamine.","volume":"38","author":"Qi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1124\/dmd.111.039727","article-title":"Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation.","volume":"39","author":"Uchaipichat","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bja.2017.11.081","article-title":"Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability.","volume":"120","author":"Lilius","year":"2018","journal-title":"Br J Anaesth"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/bph.12974","article-title":"Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.","volume":"172","author":"Lilius","year":"2015","journal-title":"Br J Pharmacol"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bcpt.12941","article-title":"Interactions of (2S,6S;2R,6R)-hydroxynorketamine, a secondary metabolite of (R,S)-ketamine, with morphine.","volume":"122","author":"Lilius","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R23-20250502","first-page":"1","article-title":"Human UGT2B7 catalyzes morphine glucuronidation.","volume":"25","author":"Coffman","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jpainsymman.2004.04.007","article-title":"Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.","volume":"28","author":"Michna","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/clpt.2010.113","article-title":"Statistical guide for clinical pharmacology & therapeutics.","volume":"88","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/clpt.1993.149","article-title":"Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity.","volume":"54","author":"Babul","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2125.1996.32810.x","article-title":"Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continus.","volume":"41","author":"Drake","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/bja\/53.12.1321","article-title":"Lack of effect of ketamine analgesia on gastric emptying in man.","volume":"53","author":"Grant","year":"1981","journal-title":"Br J Anaesth"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits.","volume":"77","author":"Niesters","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00134-013-2831-1","article-title":"Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study.","volume":"39","author":"Reintam Blaser","year":"2013","journal-title":"Intensive Care Med"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13054-020-02889-4","article-title":"Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine.","volume":"24","author":"Reintam Blaser","year":"2020","journal-title":"Crit Care"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0885066615620592","article-title":"Ketamine for analgosedation in the intensive care unit: a systematic review.","volume":"32","author":"Patanwala","year":"2017","journal-title":"J Intensive Care Med"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.jvca.2010.07.011","article-title":"Intraoperative infusion of S(+)-ketamine enhances post-thoracotomy pain control compared with perioperative parecoxib when used in conjunction with thoracic paravertebral ropivacaine infusion.","volume":"25","author":"Argiriadou","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1399-6576.2007.01436.x","article-title":"Bowel function after bowel surgery: morphine with ketamine or placebo; a randomized controlled trial pilot study.","volume":"51","author":"McKay","year":"2007","journal-title":"Acta Anaesthesiol Scand"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1399-6576.1998.tb05299.x","article-title":"No inhibition of gastro-intestinal propulsion after propofol- or propofol\/ketamine-N2O\/O2 anaesthesia. A comparison of gastro-caecal transit after isoflurane anaesthesia.","volume":"42","author":"Freye","year":"1998","journal-title":"Acta Anaesthesiol Scand"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/BF01809750","article-title":"Ketamine for analgosedative therapy in intensive care treatment of head-injured patients.","volume":"138","author":"Kolenda","year":"1996","journal-title":"Acta Neurochir (Wien)"},{"key":"R37-20250502","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/ANA.0b013e31811f3feb","article-title":"Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility, and need of vasopressors in patients with intracranial pathologies: a pilot study.","volume":"19","author":"Schmittner","year":"2007","journal-title":"J Neurosurg Anesthesiol"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1213\/ANE.0000000000005229","article-title":"Rifampin reduces the plasma concentrations of oral and intravenous hydromorphone in healthy volunteers.","volume":"133","author":"Lohela","year":"2021","journal-title":"Anesth Analg"},{"key":"R39-20250502","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","article-title":"Does the pharmacology of oxycodone justify its increasing use as an analgesic?","volume":"34","author":"Olkkola","year":"2013","journal-title":"Trends Pharmacol Sci"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000006640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:53Z","timestamp":1786113053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000006640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000006640","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}